Background: A major worldwide health issue impacting 1% of the global population is infection with chronic hepatitis C virus (HCV). Egypt has the greatest prevalence of HCV worldwide, representing 14.7% of the population, yet deaths from hepatocellular carcinoma (HCC) and cirrhosis remain a major problem in Egypt.

Objective: The purpose of this study is to measure the concentration of serum retinoic acid receptor responder 2 (RARRES2) as well as whether patients with CHC may benefit from using it as a further non-invasive indicator of predictive importance.

Patients and Methods: This investigation involved 40 participants. The included participants will be classified into two groups: Group I: included (25) participants with normal weight and chronic hepatitis C virus disease. Group II: included (15) healthy normal-weight subjects as a control group. Inclusion criteria: Female aged middle age 25 -45 years old, Positive anti-HCV antibody test and HCV RNA, Normal body weigh 18.5-24.9.

Results: The average level of RARRES2 was 1767.53± 2326.75 ng/ml in the HCV group and 451.51± 144.42 ng/ml in the control group. The level of RARRES2 in the HCV group was significantly greater in comparison with the control group (p=0.010).

Conclusions: The findings of the present investigation show that levels of serum chemerin rose in patients suffering from CHC and that these levels increased concurrently with the deterioration of liver functional reserves. It is possible to conclude that chemerin could be employed as an additional technique for assessing CHC prognosis and monitoring metabolic abnormalities caused by a virus.